This inventor holds 57 USPTO granted patents and 55 published patent applications, primarily in Muscle Targeting Complexes. Top assignees: Dyne Therapeutics, Inc., Hercules Capital, Inc., as Agent. Active years: 2021-2026.
Company Filing History:
56 out of 57Â 
1 out of 6Â Years Active: 2021-2026
Areas of Expertise:
Title: The Innovative Contributions of Timothy Weeden in Biomedicine
Introduction: Timothy Weeden, an accomplished inventor based in Waltham, MA, has made significant strides in the field of biotechnology with a remarkable portfolio of 36 patents. His contributions are particularly valuable in the development of muscle-targeting complexes and oligonucleotides aimed at addressing critical medical conditions.
Latest Patents: Among Timothy Weeden's latest patents is a groundbreaking innovation concerning muscle-targeting complexes that integrate an anti-transferrin receptor antibody linked to an oligonucleotide. This intellectual property outlines aspects of complexes that comprise a muscle-targeting agent covalently linked to a molecular payload. Notably, certain embodiments specify a muscle-targeting agent designed to bind to an internalizing cell surface receptor found on muscle cells. Additionally, the molecular payload is intended to inhibit either the expression or activity of DUX4, utilizing oligonucleotides such as antisense oligonucleotides or RNAi oligonucleotides. Another patent focuses on similar complexes that address a disease-associated-repeat in the DMPK allele, showcasing the versatility and applicability of his innovative approaches.
Career Highlights: Timothy Weeden has dedicated his professional journey to advancing medical science, ultimately aligning his efforts with Dyne Therapeutics, Inc. This role has allowed him to harness his expertise in targeting therapies specifically for muscle-related disorders. His impressive patent count underscores his commitment to pushing the boundaries of what is possible in biotechnology.
Collaborations: In his endeavors, Timothy collaborates closely with talented colleagues such as Mohammed T Qatanani and Romesh R Subramanian. Their combined efforts foster a dynamic environment for innovation and contribute to the development of promising therapeutic solutions.
Conclusion: Timothy Weeden exemplifies the innovative spirit of modern inventors, especially in the realm of biotechnology. His contributions through extensive patent work not only highlight his inventiveness but also serve to inspire future advancements in medical science aimed at improving the lives of patients with muscle disorders. With the continuance of his work at Dyne Therapeutics, there is great anticipation for the impact of his future inventions on health care and therapeutic strategies.